Successful treatment for solitary brain metastasis from alveolar soft part sarcoma

1995 ◽  
Vol 25 (2) ◽  
pp. 161-166 ◽  
Author(s):  
Cheng -Hsu Wang ◽  
Ning Lee ◽  
Liang -Shong Lee
Keyword(s):  
Brain Metastasis ◽  
Successful Treatment ◽  
Soft Part ◽  
Alveolar Soft Part Sarcoma ◽  
Solitary Brain Metastasis

scholarly journals Brain Metastasis of Alveolar Soft Part Sarcoma treated Successfully with Hypothermia: A Case Report

1997 ◽  
Vol 6 (6) ◽  
pp. 408-412
Author(s):  
Satoshi Sawauchi ◽  
Shigehiko Kabe ◽  
Kouichi Takahashi ◽  
Masahiko Akiyama ◽  
Ikuo Shukuya ◽  
...  
Keyword(s):  
Case Report ◽  
Brain Metastasis ◽  
Soft Part ◽  
Alveolar Soft Part Sarcoma

scholarly journals A case of multiple synchronously diagnosed brain metastases from alveolar soft part sarcoma without concurrent lung involvement

2021 ◽  
Vol 12 ◽  
pp. 111
Author(s):  
Mark A. Damante ◽  
Kristin M. Huntoon ◽  
Joshua D. Palmer ◽  
David A. Liebner ◽  
James Bradley Elder
Keyword(s):  
Soft Tissue ◽  
Brain Metastasis ◽  
Lung Metastasis ◽  
Soft Tissue Mass ◽  
Soft Part ◽  
Primary Lesion ◽  
Alveolar Soft Part Sarcoma ◽  
Lung Involvement ◽  
Tissue Mass ◽  
Intracranial Involvement

Background: Alveolar soft part sarcoma (ASPS) is a rare soft-tissue sarcoma with a propensity for early hematogenous dissemination to the lungs and frequent brain metastasis. The development of lung metastasis almost invariably precedes intracranial involvement. There are no previously reported cases in which a patient was synchronously diagnosed with ASPS and multiple brain metastasis without lung involvement. Case Description: A 29-year-old gentleman was found to have three intracranial lesions following the onset of generalized seizures. Staging studies identified a soft-tissue mass in the left thigh and an adjacent femoral lesion. Biopsy of the soft-tissue mass was consistent with ASPS. The patient then underwent neoadjuvant stereotactic radiotherapy to all three brain lesions, followed by en bloc resection of the dominant lesion. The patient was then started on a programmed death-ligand 1 (PD-L1) inhibitor. Subsequent surgical resection of the primary lesion and femur metastasis demonstrates a histopathologic complete response of the bony metastasis and partial response of the primary lesion. At present, the patient has received 14 cycles of atezolizumab without recurrence of the primary or bony lesions and the irradiated intracranial disease has remained stable without recurrence of the resected dominant lesion. Conclusion: While intracranial involvement is relatively common in ASPS, a case with multiple, synchronously diagnosed brain metastasis without concurrent lung metastasis has not been described. The presented case discusses the safety and efficacy of aggressive management of intracranial disease in the setting of atezolizumab. Prospective evaluation of the efficacy of checkpoint inhibitors and the prognostic value of PD-L1 expression in ASPS with brain metastasis are necessary.

scholarly journals Advanced Alveolar Soft Part Sarcoma Treated with Pazopanib over Three Years

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Yoji Shido ◽  
Yukihiro Matsuyama
Keyword(s):  
Brain Metastasis ◽  
Brain Metastases ◽  
Kinase Inhibitor ◽  
Lung Tumor ◽  
Lung Metastases ◽  
Soft Part ◽  
Objective Response ◽  
Alveolar Soft Part Sarcoma ◽  
Longitudinal Assessment ◽  
Metastatic Lung Tumor

Alveolar soft part sarcoma (ASPS) is a rare malignant tumor that generally occurs in adolescents and young adults. It progresses slowly, but lung and brain metastases often occur in the early phase of the clinical course, and chemotherapy has been reported as not being effective for ASPS. Pazopanib is a multitargeted tyrosine kinase inhibitor that has been clinically available from November 2012 in Japan. This is a case report of a patient presented with multiple lung metastases and unresectable primary abdominal ASPS. We initially treated this patient by systemic chemotherapy with combination use of ifosfamide and doxorubicin. Stable disease was observed without any objective response. Then, we finally started to administrate pazopanib 800 mg/day. After 25 months of pazopanib administration, slight tumor reduction and a decrease of enhancement were observed. Objective responses were achieved for both the primary tumor and metastatic lung tumor; however, a newly developed brain metastasis was subsequently identified. Based on this case, pazopanib appears effective against ASPS, except for brain metastases. This case suggests that pazopanib may be useful as a first-line drug against unresectable ASPS and that longitudinal assessment of brain metastasis should be performed in similar cases.

scholarly journals Brain Metastasis of Crystal-Deficient, CD68-Positive Alveolar Soft Part Sarcoma: Ultrastructural Features and Differential Diagnosis

2014 ◽  
Vol 39 (1) ◽  
pp. 69-77 ◽  
Author(s):  
Matthew D. Cykowski ◽  
John Hicks ◽  
David I. Sandberg ◽  
Adriana Olar ◽  
Julia A. Bridge ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Brain Metastasis ◽  
Soft Part ◽  
Alveolar Soft Part Sarcoma

Alveolar soft part sarcoma: An unusually long interval between presentation and brain metastasis

1993 ◽  
Vol 24 (9) ◽  
pp. 1030-1034 ◽  
Author(s):  
Kevin O. Lillehel ◽  
Bette Kleinschmidt-DeMasters ◽  
Dawn H. Mitchell ◽  
Elaine Spector ◽  
Carol A. Kruse
Keyword(s):  
Brain Metastasis ◽  
Soft Part ◽  
Alveolar Soft Part Sarcoma

scholarly journals RADI-04. Stereotactic radiosurgery in alveolar soft part sarcoma brain metastasis

2021 ◽  
Vol 3 (Supplement_3) ◽  
pp. iii18-iii18
Author(s):  
Jia Xu Lim ◽  
Bengt Karlsson ◽  
Angela Pang ◽  
Vellayappan Balamurugan ◽  
Vincent Nga
Keyword(s):  
Local Recurrence ◽  
Brain Metastasis ◽  
Stereotactic Radiosurgery ◽  
Radiation Effects ◽  
Low Dose ◽  
Soft Part ◽  
Tumour Volume ◽  
Alveolar Soft Part Sarcoma ◽  
High Dose ◽  
Dose Regime

Abstract Background Alveolar soft part sarcoma (ASPS), although rare, has the highest incidence of brain metastasis amongst all sarcomas. Stereotactic radiosurgery (SRS) has been shown to be a well tolerated and effective treatment of intracranial sarcomatous metastasis. However, there is a paucity of published literature that guides radiation therapy in this condition. Methods This is a single centre retrospective review of all ASPS patients with intraparenchymal brain metastasis in our centre treated with stereotactic radiosurgery (SRS). SRS dosing is dichotomised into high and low dose (≥25 Gy and <25 Gy respectively) and outcomes such as local recurrence (LR) and radiation effects are noted. Successful treatment was defined as a lesion that regressed, is stable, or has less than 25% increase in tumour volume. Local recurrence (LR) was defined as increase in tumour volume by more than 25% during follow up. Results There were three patients with 11 ASPS metastatic brain lesions, one of which underwent retreatment. Each lesion was followed up for a mean duration of 12 months (range: 5 – 22 months). Five lesions treated with a high dose regime and six lesions were given low dose. Lesions treated with high dose SRS experienced significantly less LR (20% vs 83.3%, OR 20.0 [95%CI 0.93 – 430), p = 0.036) with no increase in undue symptomatic radiation effects. Retreatment of lesions with LR after initial SRS using a low dose regime was successful, albeit only in the single recurrent lesion. Conclusions We conclude that SRS can be used as a first line treatment for ASPS brain metastasis that are not surgically accessible and that using a high dose for treatment is effective and safe. Multicentre collaborative studies can be performed to validate this claim.

Sign in / Sign up

Export Citation Format

Share Document